Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Aprea Therapeutics Inc (APRE)

Aprea Therapeutics Inc (APRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Aprea Therapeutics Initiates Twice Daily Dosing of ATRN-119 in Phase 1/2a Clinical Trial to Enhance Cancer Treatment Efficacy

Aprea Therapeutics initiates twice daily dosing of ATRN-119 in cancer trial to enhance efficacy and optimize patient outcomes.Quiver AI SummaryAprea Therapeutics has initiated a twice daily dosing regimen...

APRE : 3.05 (-5.57%)
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

APRE : 3.05 (-5.57%)
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

APRE : 3.05 (-5.57%)
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

APRE : 3.05 (-5.57%)
Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

APRE : 3.05 (-5.57%)
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

APRE : 3.05 (-5.57%)
Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

APRE : 3.05 (-5.57%)
Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has...

PHAR : 9.10 (+1.79%)
KA : 0.5746 (-30.69%)
APRE : 3.05 (-5.57%)
XFOR : 0.6113 (+0.66%)
Biotech Bid Up Following First Patient Dosage

A Boston-based %Biotech company is turning heads on Wednesday after the company announced that the first patient was dosed in its Phase 1/2a monotherapy clinical trial of ATRN-119, the Company’s lead...

APRE : 3.05 (-5.57%)
Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing...

APRE : 3.05 (-5.57%)

Barchart Exclusives

Is It Time to Sell This Second-Fiddle AI Stock Before 2025?
Bank of America has cut its rating on AMD while lowering its price target. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar